ABEOライブシグナル | Getagraph.comで利益を最大化

買う 107847 min ago

@ $6.00

発行日: 15 2月 2024 @ 04:22

リターン: -37.44%

前回のシグナル: 2月 15 - 03:08

前回のシグナル: 売る

リターン: -5.73 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:49):

Stats
本日の出来高	1.48M
平均出来高	527 064
時価総額	102.68M
EPS	$0 ( 2024-04-03 )
次の収益日	( $-0.470 ) 2024-05-09
Last Dividend	$3 706.25 ( 2000-03-31 )
Next Dividend	$0 ( N/A )
P/E	-1.480
ATR14	$0.0200 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-25	Seshadri Vishwas	Buy	10 000	Common Stock
2024-04-26	Charles Faith L.	Buy	7 550	Common Stock
2024-04-25	O'malley Brendan M.	Buy	8 600	Common stock
2024-04-25	Vazzano Joseph Walter	Buy	5 608	Common stock
2024-03-15	Vazzano Joseph Walter	Sell	703	Common stock

INSIDER POWER
82.71
Last 95 transactions
Buy: 4 778 989 \| Sell: 610 127

ボリューム相関

長: -0.25 (neutral)

短: -0.05 (neutral)

Signal:(58.939) Neutral

Abeona Therapeutics Inc 相関

10 最も正の相関
NVDA	0.94
COOL	0.939
BOTZ	0.938
OPRA	0.935
SVAC	0.932
AVGO	0.924
SMCI	0.923
ADVM	0.923
DFH	0.922
TQQQ	0.921

10 最も負の相関
AMRB	-0.953
LWAC	-0.916
NETE	-0.915
SOPA	-0.913
ONCR	-0.909
PHCF	-0.907
SRAC	-0.9
PRDO	-0.89
QTEK	-0.888
AGFS	-0.887

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Abeona Therapeutics Inc 相関 - 通貨/商品

0.08
( neutral )

0.01
( neutral )

0.00
( neutral )

0.70
( moderate )

0.26
( neutral )

Abeona Therapeutics Inc 財務諸表

Annual	2023
収益:	$3.50M
総利益:	$302 000 (8.63 %)
EPS:	$-2.53

FY	2023
収益:	$3.50M
総利益:	$302 000 (8.63 %)
EPS:	$-2.53

FY	2022
収益:	$1.41M
総利益:	$964 000 (68.18 %)
EPS:	$-4.05

FY	2021
収益:	$3.00M
総利益:	$3.00M (100.00 %)
EPS:	$-21.57

Financial Reports:

No articles found.

Abeona Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Abeona Therapeutics Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$3 706.25	2000-03-31
Last Dividend	$3 706.25	2000-03-31
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$3 706.25	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2000	$3.00	0.03%
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$0	0.00%
2005	$0	0.00%
2006	$0	0.00%
2007	$0	0.00%
2008	$0	0.00%
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-15.48	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.847	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-3.34	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.10	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.103	1.500	4.98	7.47	[0.2 - 2]
debtRatioTTM	0.0844	-1.500	8.59	-10.00	[0 - 0.6]
interestCoverageTTM	-115.31	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.448	2.00	-0.483	-0.965	[0 - 30]
freeCashFlowPerShareTTM	-1.461	2.00	-0.731	-1.461	[0 - 20]
debtEquityRatioTTM	0.364	-1.500	8.54	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0863	1.000	-1.895	-1.895	[0.2 - 0.8]
operatingProfitMarginTTM	-13.77	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-6.85	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0547	0.800	-2.97	-2.38	[0.5 - 2]
Total Score				-2.42

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-1.537	1.000	-0.256	0	[1 - 100]
returnOnEquityTTM	-3.34	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.461	2.00	-0.487	-1.461	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.448	2.00	-0.483	-0.965	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0712	1.500	-2.86	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-10.57	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.65

Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.